Sartor O - Search Results

1

A Whole Blood Assay for AR-V7 and AR^v567es in Patients with Prostate Cancer.

Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, Dong Y, Sartor O, Zhang H. Liu X, et al. Among authors: sartor o. J Urol. 2016 Dec;196(6):1758-1763. doi: 10.1016/j.juro.2016.06.095. Epub 2016 Jul 20. J Urol. 2016. PMID: 27449259 Free PMC article.

2

Determination of CAG repeat length in the androgen-receptor gene using frozen serum.

Sartor O, Zheng Q. Sartor O, et al. Urology. 1997 Feb;49(2):301-4. doi: 10.1016/S0090-4295(96)00549-3. Urology. 1997. PMID: 9037303

3

Influence of hepatic function on serum levels of prostate specific antigen.

Williams PB, Eastham JA, Culkin DJ, Mata JA, Venable DD, Sartor O. Williams PB, et al. Among authors: sartor o. J Urol. 1997 Nov;158(5):1867-9. doi: 10.1016/s0022-5347(01)64149-1. J Urol. 1997. PMID: 9334619

4

Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.

Eastham JA, Sartor O. Eastham JA, et al. Among authors: sartor o. J Urol. 1998 Mar;159(3):990. J Urol. 1998. PMID: 9474206 No abstract available.

5

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.

Sartor O, Weinberger M, Moore A, Li A, Figg WD. Sartor O, et al. Urology. 1998 Aug;52(2):252-6. doi: 10.1016/s0090-4295(98)00149-6. Urology. 1998. PMID: 9697790 Clinical Trial.

6

Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer.

Sartor O, Zheng Q, Eastham JA. Sartor O, et al. Urology. 1999 Feb;53(2):378-80. doi: 10.1016/s0090-4295(98)00481-6. Urology. 1999. PMID: 9933058

7

Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer.

Kubricht WS, Kattan MW, Sartor O, Eastham JA. Kubricht WS, et al. Among authors: sartor o. Urology. 1999 Mar;53(3):553-6. doi: 10.1016/s0090-4295(98)00548-2. Urology. 1999. PMID: 10096383

8

Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL.

Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Eastham JA, et al. Among authors: sartor o. Urology. 1999 Oct;54(4):709-13. doi: 10.1016/s0090-4295(99)00213-7. Urology. 1999. PMID: 10510933

9

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C; Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Carroll PR, et al. Among authors: sartor o. Urology. 2002 Sep;60(3 Suppl 1):1-6. doi: 10.1016/s0090-4295(02)01559-5. Urology. 2002. PMID: 12231036 Review. No abstract available.

10

Endpoints in prostate cancer clinical trials.

Sartor O. Sartor O. Urology. 2002 Sep;60(3 Suppl 1):101-7; discussion 107-8. doi: 10.1016/s0090-4295(02)01585-6. Urology. 2002. PMID: 12231062 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

503 results

Search Page